{"denoms":[{"counts":[{"groupId":"BG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"BG000","title":"ALK-positive Solid Tumors"}],"measures":[{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}